Date:11/4/2009

2009 (1) 2009 (1) ---- ---- ---- ---- Other income and (expense) on a GAAP basis $3,873 $(651) $592 $(1,607) Impact of adoption of ASC 470-20 1,945 1,825 5,659 5,219 Unrealized gain on embedded Derivative instrument on HeartWare loan (5,240) - (5,240) - ------ --- ------ --- Other income on a non-GAAP basis $578 $1,174 $1,011 $3,612 ==== ====== ====== ====== (1) Adjusted for the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt. The following table reconciles the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income. THORATEC CORPORATION GAAP to Non-GAAP Tax Expense Reconciliation (Unaudited) (in thousands) Three Months Ended Nine Months Ended ------------------ ----------------- September September 27, 27, October 2008 As October 2008 As 3, Adjusted 3, Adjusted 2009 (1) 2009 (1) ---- ---- ---- ---- Tax expense on a GAAP basis $(5,684) 32.6% $(1,478) 19.6% $(8,483) 30.6% $(3,793) 22.6% Share-based compensation exp
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA